Apr 6 |
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen impressive returns of 146% over the past five years
|
Apr 5 |
Should You Sell This Stock Following a Regulatory Roadblock?
|
Apr 4 |
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
|
Apr 4 |
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
|
Apr 1 |
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
|
Apr 1 |
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
|
Apr 1 |
Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval
|
Mar 28 |
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
|
Mar 28 |
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
|
Mar 28 |
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
|